scholarly journals Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial

2020 ◽  
Vol 22 (7) ◽  
pp. 1141-1150 ◽  
Author(s):  
Subodh Verma ◽  
Abhinav Sharma ◽  
Bernard Zinman ◽  
Anne Pernille Ofstad ◽  
David Fitchett ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Risk Score ◽  
Post Hoc Analysis ◽  
Risk Of Mortality ◽  
Outcome Trial ◽  
Post Hoc

scholarly journals Additive beneficial effects of beta blockers in the prevention of symptomatic heart failure

2016 ◽  
Vol 72 (1) ◽  
Author(s):  
Alberto Genovesi Ebert ◽  
Furio Colivicchi ◽  
Marco Malvezzi Caracciolo ◽  
Carmine Riccio
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Heart Disease ◽  
Beta Blockers ◽  
Structural Heart Disease ◽  
Symptomatic Heart Failure ◽  
Post Hoc Analysis ◽  
Lv Dysfunction ◽  
History Of ◽  
Post Hoc

The prevention of symptomatic heart failure represents the treatment of patients in the A and B stages of AHA/ACC heart failure classification. Stage A refers to patients without structural heart disease but at risk to develop chronic heart failure. The major risk factors in stage A are hypertension, diabetes, atherosclerosis, family history of coronary artery disease and history of cardiotoxic drug use. In this stage, blockers hypertension is the primary area in which beta blockers may be useful. Beta blockers seem not to be superior to other medication in reducing the development of heart failure due to hypertension. Stage B heart failure refers to structural heart disease but without symptoms of heart failure. This includes patients with asymptomatic valvular disease, asymptomatic left ventricular (LV) dysfunction, previous myocardial infarction with or without LV dysfunction. In asymptomatic valvular disease no data are available on the efficacy of beta blockers to prevent heart failure. In asymptomatic LV dysfunction only few asymptomatic patients have been enrolled in the trials which tested beta blockers. NYHA I patients were barely 228 in the MDC, MERIT and ANZ trials altogether. The REVERT trial was the only trial focusing on NYHA I patients with LV ejection fraction less than 40%. Metoprolol extended release on top of ACE inhibitors ameliorated LV systolic volume and ejection fraction. A post hoc analysis of the SOLVD Prevention trial demonstrated that beta blockers reduced death and development of heart failure. Similar results were reported in post MI patients in a post hoc analysis of the SAVE trial (Asymptomatic LV failure post myocardial infarction). In the CAPRICORN trial about 65% of the patients were not taking diuretics and then could be considered asymptomatic. The study revealed a reduction in mortality and a non-significant trend toward reduction of death and hospital admission for heart failure. Conclusions: beta blockers are not specifically indicated in stage A heart failure. On the contrary, in most of the stage B patients, and particularly after MI, beta blockers are indicated to reduce mortality and, probably, also the progression toward symptomatic heart failure.

A low pulse pressure predicts mortality in subjects with heart failure after an acute myocardial infarction: a post-hoc analysis of the CAPRICORN study

2011 ◽  
Vol 101 (1) ◽  
pp. 29-35 ◽  
Author(s):  
Colin J. Petrie ◽  
Adriaan A. Voors ◽  
Michele Robertson ◽  
Dirk J. van Veldhuisen ◽  
Henry J. Dargie
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Pulse Pressure ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Relative hyperglycemia is associated with complications following an acute myocardial infarction: a post-hoc analysis of HI-5 data

2017 ◽  
Vol 16 (1) ◽  
Author(s):  
Tien F. Lee ◽  
Morton G. Burt ◽  
Leonie K. Heilbronn ◽  
Arduino A. Mangoni ◽  
Vincent W. Wong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial

2017 ◽  
Vol 5 (5) ◽  
pp. 333-340 ◽  
Author(s):  
Jelena P Seferovic ◽  
Brian Claggett ◽  
Sara B Seidelmann ◽  
Ellen W Seely ◽  
Milton Packer ◽  
...  
Keyword(s):  
Heart Failure ◽  
Glycaemic Control ◽  
Post Hoc Analysis ◽  
Patients With Heart Failure ◽  
Post Hoc

scholarly journals Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et

2018 ◽  
Vol 5 (6) ◽  
pp. 1069-1071 ◽  
Author(s):  
Felix J.A. Ramires ◽  
Felipe Martinez ◽  
Efraín A. Gómez ◽  
Caroline Demacq ◽  
Claudio R. Gimpelewicz ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Disease ◽  
Safety Profile ◽  
Post Hoc Analysis ◽  
Chagas Cardiomyopathy ◽  
Shift Trial ◽  
Chagas Heart Disease ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document